Af­ter fil­ing for au­tho­riza­tion of its Covid-19 an­ti­body as a pro­phy­lac­tic, As­traZeneca pulls out new da­ta in the treat­ment set­ting

Less than a week af­ter As­traZeneca made its pitch to the FDA for emer­gency use of its mon­o­clon­al an­ti­body com­bo for Covid-19 pro­phy­lax­is, the British phar­ma is fol­low­ing up with da­ta that show the drug’s po­ten­tial as a treat­ment as well.

AZD7442 re­duced the risk of se­vere Covid-19 or death by 50% com­pared to place­bo in a group of 407 out­pa­tients who were giv­en the an­ti­body with­in sev­en days of de­vel­op­ing symp­toms, As­traZeneca re­vealed on Mon­day. That adds up to 18 events in the treat­ment arm, and 37 in the place­bo arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER